Clinical Trials Browser

Phase 2 × Leukemia, Prolymphocytic, T-Cell × Alemtuzumab × Clear all

NCT01186640 2022-01-05

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell